SK Pharmteco to Compete for Overseas Contract Development and Manufacturing of Pharmaceuticals

SK Inc.'s pharmaceutical contract development and manufacturing organization (CDMO) integrated corporation, SK Pharmteco, is entering the overseas bidding market.

From the 24th (local time) to the 26th, SK Pharmteco will set up its largest-ever exhibition booth measuring 189㎡ at 'CPHI,' the world's largest biopharmaceutical conference held in Barcelona, Spain. The exhibition location has also shifted from the previous active pharmaceutical ingredients (API) section to the contract manufacturing and services area where major global CDMOs are located.

SK Pharmteco CPHI Barcelona 2023 Booth Aerial View

Key executives from subsidiaries, including SK Pharmteco CEO Yog Algrim, Ampac, SK Biotek Ireland and Eposkesh, as well as CBM, a US cell and gene therapy CDMO company whose management rights SK Pharmteco secured last month, are also expected to attend in large numbers.

At the exhibition, SK Pharmteco plans to showcase its unique competitive strengths to potential customers, including ▲a global supply chain spanning the US, Europe, and Asia ▲service capabilities that provide the entire process from development, production, and analysis of cell and gene therapy raw materials to finished products all in one place ▲and continuous process technology for synthetic active pharmaceutical ingredient production.

SK Pharmteco's continuous process technology for synthetic active pharmaceutical ingredients was recognized for its technological competitiveness by being selected as a finalist in the Accelerating Innovation category at this year's exhibition. The continuous process technology produces products in an uninterrupted, continuous flow at each process stage through automation, offering superior cost, productivity, quality, and safety compared to traditional methods, while significantly reducing waste volume.

CEO Yog Algrim stated, "Through securing management rights of CBM, we are accelerating a new leap forward in the bio business by acquiring large-scale cell and gene therapy production facilities in the US and Europe," adding, "We will create various opportunities to grow into a company with the world's top-level competitiveness from synthesis to biopharmaceuticals."

SK Pharmteco, a global CDMO integrated corporation established by SK Inc., operates a total of seven business sites and five research and development (R&D) centers across the US, Europe, and Korea. Recently, SK Pharmteco established the position of Chief Commercial Officer (CCO) and strengthened its global integrated marketing functions. Andrew Penny, who previously served as Chief Commercial Officer at the global CDMO Fujifilm Diosynth Biotechnology, was appointed as the new CCO.

This content was produced with the assistance of AI translation services.